산학융합 아이콘 플랫폼
메뉴

연구인력 상세보기

연구인력 정보

아이콘

정승현

Seung-Hyun Jeong

예방약학

기타생물약학

정보

전화번호 061-750-3757

이메일 jeongsh@scnu.ac.kr

연구인력 상세정보

순번 연구분야 연구핵심명
내역이 존재하지 않습니다.

연구과제

순번 과제명 기관명 기간
1 생체정보에 따른 생리학 기반 독성동태 모델 최적화 연구 식품의약품안전평가원 20230426~20230925
2 (교내) 분지형 옥틸페놀의 체내 독성동태학 특성 탐색 및 모델화 순천대학교 20230401~20240229
3 약물계량 모델리에 기반한 의약품들의 과학적 임상용법 탐색과 유효성 및 안전성 개선 한독제석재단 20230301~20240229
4 타겟 의약품의 체내 약물계량 모델 개발과 이를 활용한 임상 시뮬레이션 적용 및 생물학적동등성 시험의 체계적 계획 설립 일반기업체 20250101~20251231
5 약물계약모델링 기술들을 활용한 첨단 정밀 임상용법 개발 연구 순천대학교 20240701~20250228

학술논문

순번 제목 기관명 기간
1 Physiologically Based Pharmacokinetic (PBPK) Modeling of Lornoxicam: Exploration of doses for CYP2C9 Genotypes and Patients with Cirrhosis Elsevier B.V. 202211
2 Development of physiologically-based toxicokinetic-toxicodynamic (PBTK-TD) model for 4-nonylphenol (4-NP) reflecting physiological changes according to age in males: Application as a new risk assessment tool with a focus on toxicodynamics Elsevier Ltd 202211
3 Torsemide Pharmacometrics in Healthy Adult Populations Including CYP2C9 Genetic Polymorphisms and Various Patient Groups through Physiologically Based Pharmacokinetic-Pharmacodynamic Modeling MDPI 202212
4 Dosage exploration of meloxicam according to CYP2C9 genetic polymorphisms based on a population pharmacokinetic-pharmacodynamic model American College of Clinical Pharmacy 202301
5 Human risk assessment of 4-n-nonylphenol (4-n-NP) using physiologically based pharmacokinetic (PBPK) modeling: analysis of gender exposure differences and application to exposure analysis related to large exposure variability in population SPRINGER HEIDELBERG 202210
6 Drug delivery to the brain via the nasal route of administration: exploration of key targets and major consideration factors SPRINGERNATURE 202301
7 Population Pharmacokinetic Modeling of Zaltoprofen in Healthy Adults: Exploring the Dosage Regimen MDPI 202301
8 Establishment of a fexofenadine population pharmacokinetic (PK)？pharmacodynamic (PD) model and exploration of dosing regimens through simulation 한국약제학회 202305
9 Quantitative assessment of the relevance of organic-anion-transporting-polypeptide 1B1 and 2B1 polymorphisms in fexofenadine pharmacokinetic variants via pharmacometrics ELSEVIER 202306
10 Modeling population pharmacokinetics of morniflumate in healthy Korean men: extending pharmacometrics analysis to niflumic acid, its major active metabolite SPRINGER 202308
11 Inter-individual exposure variability interpretation through reflection of biological age algorithm in physiologically based toxicokinetic model: Application to human risk assessment of di-isobutyl-phthalate ELSEVIER SCI LTD 202311
12 P-glycoprotein mechanical functional analysis using in silico molecular modeling: Pharmacokinetic variability according to ABCB1 c.2677G > T/A genetic polymorphisms Elsevier 202309
13 A population pharmacokinetic model for individualized regimens of finasteride according to CYP3A5 genotype and liver function Springer Science and Business Media Deutschland GmbH 202310
14 Exploring Differences in Pharmacometrics of Rabeprazole between Genders via Population Pharmacokinetic？Pharmacodynamic Modeling MDPI 202311
15 Population pharmacokinetic modeling of levodropropizine: extended application to comparative analysis between commercial formulations and exploration of pharmacokinetic effects of diet Springer Nature 202312
16 Is Gender an Important Factor in the Precision Medicine Approach to Levocetirizine? MDPI 202401
17 Sex differences in 4-tert-octylphenol toxicokinetics: Exploration of sex as an effective covariate through an in vivo modeling approach Elsevier 202401
18 Pharmacokinetic Analysis of Levodropropizine and Its Potential Therapeutic Advantages Considering Eosinophil Levels and Clinical Indications MDPI 202402
19 Quantitative summary on the human pharmacokinetic properties of cannabidiol to accelerate scientific clinical application of cannabis Springer Nature 202406
20 Exploring gender differences in pharmacokinetics of central nervous system related medicines based on a systematic review approach Springer Nature 202406
21 Development of Hsp90 inhibitor to regulate cytokine storms in excessive delayed- and acute inflammation Elsevier 202406
22 Structure-Based Analysis of Cefaclor Pharmacokinetic Diversity According to Human Peptide Transporter-1 Genetic Polymorphism MDPI 202406
23 Human risk assessment through development and application of a physiologically based toxicokinetic model for 4-tert-octylphenol Elsevier 202407
24 Population Pharmacokinetics of Loxoprofen and its alcoholic metabolites in healthy Korean men Springer Nature 202408
25 Population pharmacokinetic modeling study and discovery of covariates for the antidepressant sertraline, a serotonin selective reuptake inhibitor Elsevier Ltd 202410
26 Pharmacokinetic Prediction of Immediate- and Extended-Release Tablets for Patients with Liver Disease Using Whole Body Physiologically-Based Pharmacokinetic Modeling for the Antipsychotic Drug Quetiapine Springer Nature 202501
27 Considerations of sex in bioequivalence assessments: does sex affect pharmacokinetic variability between evaluation formulations? Springer Nature 202502
28 Exposure risk assessment through toxicodynamics assessment of 4-tert-octylphenol and estimation of new reference values based on human tissue toxicity Elsevier 202505
29 Current Status of Development of Oral Formulations Combining Omega-3 Fatty Acids and Statin Ingredients and Prospects for New Formulations Springer Nature 202503
30 Development of a Physiologically-Based Pharmacokinetic Model for Quantitative Interpretation of Transdermal Drug Delivery of Rotigotine, a Dopamine Agonist for Treating Parkinson’s Disease Springer Nature 202503
31 Interpretation of the Transcriptome-Based Signature of Tumor-Initiating Cells, the Core of Cancer Development, and the Construction of a Machine Learning-Based Classifier MDPI 202508
32 Structure-based analysis of heme oxygenase subtype-selective inhibition activity of tumor-initiating cell near-infrared probe: a promising therapeutic agent for metastatic lung cancer ELSEVIER 202507
33 Exposure risk assessment of di(2-ethylhexyl)phthalate (DEHP) using human population pharmacokinetic modeling of DEHP and its major in vivo metabolites SPRINGER HEIDELBERG 202509
34 Emerging roles of heme oxygenase 2 (HO-2) in cancer: Implications for diagnosis and therapy ELSEVIER 202601
35 Unraveling the impact of renal impairment and renal replacement therapy modalities on fluconazole pharmacokinetics Springer Nature 202511
36 Population modeling of pharmacokinetic variability of epinastine, a histamine H1 receptor antagonist, according to cytochrome P450 2D6 phenotypic polymorphisms Springer Nature 202511
37 Analysis of immune cell remodeling and functional alterations induced by aging and obesity in mice Elsevier 202512

학술서적

순번 제목 출판사 출판일
내역이 존재하지 않습니다.

지식재산권

순번 제목 분류명 등록일
1 4-tert-octylphenol에 대한 생리학적 기반 독성동태학 모델 개발 및 적용을 통한 인체 위해 평가방법 출원 2024.09.27
2 록소프로펜과 그 주요 활성 대사체들에 대한 집단 약동학 모델링 기술 개발을 통한 과학적임상 용법 탐색 출원 2024.09.27
3 실리코 분자 모델링을 이용한 P-글리코단백질 기계적 기능 분석방법 출원 2024.10.25
4 CYP3A5 유전자형 및 간 기능에 따른 피나스테라이드의 개별화된 처방을 위한 집단 약동학모델을 이용한 피나스테라이드 처방방법 출원 2024.10.28
5 피나스테리드의 혈중 약물 농도 예측 방법 출원 2024.10.25
6 레보드로프로피진의 인구 약동학 모델링을 활용한 상업적 제형 간의 비교 분석에 대한 확장된 응용 및 식이의 약동학 효과 탐색 출원 2024.12.10
7 항우울제 세르트랄린에 대한 범용적 집단 약물계량 모델의 개발과 정밀의학 적용을 위한 신규 유효 공변량들의 발굴방법 출원 2024.12.13
8 4-tert-octylphenol 독성 동태학에서의 성별 차이 생체 내 모델링 접근법을 통한 효과적인 공변량으로서의 성 탐색방법 출원 2024.12.04
9 간기능 저하 환자의 정량적 약물 투여 조절을 위한 Quetiapine 기반 전신 생리학 기반 약동학 모델 및 이를 이용한 제형별 용량 조절 방법 출원 2025.04.15
10 성별 기반 생물학적 동등성 판단을 위한 약동학 평가 시스템 및 이를 이용한 제형 간 동등성판별 방법 출원 2025.04.15
11 경피약물전달제용 로티고틴의 정량 예측을 위한 생리학 기반 약동학 모델 및 이를 이용한조직 내 약물 분포 예측 방법 출원 2025.04.15
12 인체 조직 독성 기반 화학물질 위해도 평가를 위한 통합 PBTK-TD 모델 및 이를 이용한 노출량 예측 방법 출원 2025.04.15
13 오메가-3 지방산 및 스타틴 성분을 포함하는 물리적 분리형 충진 캡슐 제형 및 이의 제조 방법 출원 2025.04.15
목록